CliffBio
small molecule

REVATIO

SILDENAFIL CITRATE

Loss of exclusivityJanuary 2030FDA regulatory exclusivity expiry
CompanyVIATRIS SPECIALTY LLC

Drug detail

Brand nameREVATIO
Active ingredientSILDENAFIL CITRATE
StrengthEQ 20MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 2005
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE-469January 2030
M-287January 2026

More from VIATRIS SPECIALTY LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

REVATIO patent cliff — loss of exclusivity January 2030 | CliffBio